Cannabinoid Derived Pharmaceutical Market Size is valued at USD 12.6 Billion in 2024 and is predicted to reach USD 81.1 Billion by the year 2034 at an 20.8% CAGR during the forecast period for 2025-2034.
Cannabinoids are naturally occurring compounds derived from the Cannabis sativa plant. In recent years, Cannabinoids/medical marijuana have witnessed increased attention due to its growing therapeutic applications in human medicine. Cannabinoid’s active components are potentially effective in treating a variety of conditions, including chronic pain, cancer pain, depression, anxiety disorders, sleep disturbances, and neurological disorders. The recent upsurge in the use and acceptance of CBD can be principally attributed to the onset of cannabis legalization across the United States. Most recently, the passage of the 2018 Farm Bill, which legalized the cultivation of hemp – cannabis with less than 0.3 percent THC by weight.
The demand for cannabinoid extracts and isolates is expected to grow exponentially in the coming years, on account of the anticipated shift in consumer preferences for derivative cannabis product formats, and the applications for cannabinoids in pharmaceutical applications. The market is also driven by growing awareness about the therapeutic benefits paired with healing properties associated with cannabidiol (CBD). Moreover, cannabidiol (CBD) is widely used in several medical applications such as treatment of anxiety and depression, stress relief, diabetes prevention, mitigation of pain, alleviation of cancer symptoms, and acne reduction. The market is expected to show lucrative opportunities over the forecast period owing to the augmented adoption of CBD-based products for treating various medical conditions.
The global Cannabinoid Derived Pharmaceutical market is segmented on the basis of product, application, and region. Based on the products, the market is divided into Cannabinoid Receptor Type 1 (CB1), Cannabinoid Receptor Type 2 (CB2), and Others. On the basis of application type, the market is segmented into Alzheimer’s Disease, Autism, Cancer, Chronic Pain, Epilepsy, Migraine, Multiple Sclerosis, Schizophrenia, and Others. By Formulation segment the market is divided into Oils and Tinctures, Capsules and Tablets, Oral Sprays, Topicals, Others. The Cannabinoid Type category comprises Cannabidiol (CBD), Tetrahydrocannabinol (THC), Others. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that, Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of the forecast period.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 12.6 Bn |
|
Revenue Forecast In 2034 |
USD 81.1 Bn |
|
Growth Rate CAGR |
CAGR of 20.8% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, By Molecule Type, By Disease Indication, by cannabinoid type, by formulation |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; Japan; Brazil; Mexico ; France; Italy; Spain; China; Japan; India; South Korea; South East Asia |
|
Competitive Landscape |
Cara Therapeutics, Inc., Arena Pharmaceuticals, Cannabics Pharmaceuticals Inc., Echo Pharmaceuticals, GW Pharmaceuticals, InMed Pharmaceuticals, INSYS Therapeutics, Inc., LaraPharm, MGC Pharmaceuticals, Ltd., One World Cannabis, Orpheus Medica, Receptor Life Sciences, RespireRx Pharmaceuticals, Tetra Bio-Pharma, Cardiol Therapeutics, United cannabis Corporation, Zynerba Pharmaceuticals, and List of Other Prominent Players. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Cannabinoid Derived Pharmaceutical Market Snapshot
Chapter 4. Global Cannabinoid Derived Pharmaceutical Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Porter's Five Forces Analysis
4.7. Incremental Opportunity Analysis (US$ MN), 2024-2034
4.8. Global Cannabinoid Derived Pharmaceutical Market Penetration & Growth Prospect Mapping (US$ Mn), 2024-2034
4.9. Competitive Landscape & Market Share Analysis, By Key Player (2024)
4.10. Use/impact of AI on Cannabinoid Derived Pharmaceutical Market Industry Trends
Chapter 5. Cannabinoid Derived Pharmaceutical Market Segmentation 1: By Products, Estimates & Trend Analysis
5.1. Market Share by Products, 2023 & 2034
5.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Products:
5.2.1. Natural (Plant-derived)
5.2.1.1. Epidiolex
5.2.1.2. Sativex
5.2.1.3. Other Pipeline Products
5.2.2. Synthetic Cannabinoid
5.2.2.1. Marinol (dronabinol)
5.2.2.2. Syndros (dronabinol)
5.2.2.3. Cesamet (nabilone)
5.2.2.4. Other Pipeline Products
Chapter 6. Cannabinoid Derived Pharmaceutical Market Segmentation 2: By Molecule Type, Estimates & Trend Analysis
6.1. Market Share by Molecule Type, 2023 & 2034
6.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Molecule Type:
6.2.1. Cannabinoid Receptor Type 1 (CB1)
6.2.2. Cannabinoid Receptor Type 2 (CB2)
6.2.3. Others
Chapter 7. Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Disease Indication, Estimates & Trend Analysis
7.1. Market Share by Disease Indication, 2023 & 2034
7.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Disease Indication:
7.2.1. Alzheimer's Disease
7.2.2. Autism
7.2.3. Cancer
7.2.4. Chronic Pain
7.2.5. Epilepsy
7.2.6. Migraine
7.2.7. Multiple Sclerosis
7.2.8. Schizophrenia
7.2.9. Others
Chapter 8. Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Formulation, Estimates & Trend Analysis
8.1. Market Share by Formulation, 2023 & 2034
8.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Formulation:
8.2.1. Oils and Tinctures
8.2.2. Capsules and Tablets
8.2.3. Oral Sprays
8.2.4. Topicals
8.2.5. Others
Chapter 9. Cannabinoid Derived Pharmaceutical Market Segmentation 3: By Cannabinoid Type, Estimates & Trend Analysis
9.1. Market Share by Cannabinoid Type, 2023 & 2034
9.2. Market Size Revenue (US$ Million) & Forecasts and Trend Analyses, 2021 to 2034 for the following Cannabinoid Type:
9.2.1. Cannabidiol (CBD)
9.2.2. Tetrahydrocannabinol (THC)
9.2.3. Others
Chapter 10. Cannabinoid Derived Pharmaceutical Market Segmentation 5: Regional Estimates & Trend Analysis
10.1. Global Cannabinoid Derived Pharmaceutical Market, Regional Snapshot 2023 & 2034
10.2. North America
10.2.1. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
10.2.1.1. US
10.2.1.2. Canada
10.2.2. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.2.3. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.2.4. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.2.5. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.2.6. North America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
10.3. Europe
10.3.1. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
10.3.1.1. Germany
10.3.1.2. U.K.
10.3.1.3. France
10.3.1.4. Italy
10.3.1.5. Spain
10.3.1.6. Rest of Europe
10.3.2. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.3.3. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.3.4. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.3.5. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.3.6. Europe Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
10.4. Asia Pacific
10.4.1. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
10.4.1.1. India
10.4.1.2. China
10.4.1.3. Japan
10.4.1.4. Australia
10.4.1.5. South Korea
10.4.1.6. Hong Kong
10.4.1.7. Southeast Asia
10.4.1.8. Rest of Asia Pacific
10.4.2. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.4.3. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.4.4. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.4.5. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.4.6. Asia Pacific Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
10.5. Latin America
10.5.1. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Country, 2024-2034
10.5.1.1. Brazil
10.5.1.2. Mexico
10.5.1.3. Rest of Latin America
10.5.2. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.5.3. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.5.4. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.5.5. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.5.6. Latin America Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
10.6. Middle East & Africa
10.6.1. Middle East & Africa Wind Turbine Rotor Blade Market Revenue (US$ Million) Estimates and Forecasts by country, 2024-2034
10.6.1.1. GCC Countries
10.6.1.2. Israel
10.6.1.3. South Africa
10.6.1.4. Rest of Middle East and Africa
10.6.2. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Product, 2024-2034
10.6.3. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Molecule Type, 2024-2034
10.6.4. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Formulation, 2024-2034
10.6.5. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Cannabinoid Type, 2024-2034
10.6.6. Middle East & Africa Cannabinoid Derived Pharmaceutical Market Revenue (US$ Million) Estimates and Forecasts by Disease Indication, 2024-2034
Chapter 11. Competitive Landscape
11.1. Major Mergers and Acquisitions/Strategic Alliances
11.2. Company Profiles
11.2.1. Arena Pharmaceuticals (Pfizer)
11.2.1.1. Business Overview
11.2.1.2. Key Product/Service Overview
11.2.1.3. Financial Performance
11.2.1.4. Geographical Presence
11.2.1.5. Recent Developments with Business Strategy
11.2.2. Cannabics Pharmaceuticals Inc.
11.2.3. Cara Therapeutics, Inc.
11.2.4. Cardiol Therapeutics
11.2.5. GW Pharmaceuticals (Jazz Pharmaceuticals)
11.2.6. InMed Pharmaceuticals
11.2.7. INSYS Therapeutics, Inc.
11.2.8. LaraPharm
11.2.9. MGC Pharmaceuticals, Ltd.
11.2.10. One World Cannabis
11.2.11. Orpheus Medica
11.2.12. Receptor Life Sciences
11.2.13. RespireRx Pharmaceuticals
11.2.14. Tetra Bio-Pharma
11.2.15. United cannabis Corporation
11.2.16. Zynerba Pharmaceuticals
11.2.17. Other Prominent Players
Global Cannabinoid Derived Pharmaceutical Market, by Products, 2025-2034 (Value US$ Mn)
Global Cannabinoid Derived Pharmaceutical Market, by Molecule Type, 2025-2034 (Value US$ Mn)
Global Cannabinoid Derived Pharmaceutical Market, by Disease Indication, 2025-2034 (Value US$ Mn)
Global Cannabinoid Derived Pharmaceutical Market, by Formulation
Global Cannabinoid Derived Pharmaceutical Market, by Cannabinoid Type
Global Cannabinoid Derived Pharmaceutical Market, by Region,
North America Cannabinoid Derived Pharmaceutical Market, by Country,
Europe Cannabinoid Derived Pharmaceutical Market, by Country,
Asia Pacific Cannabinoid Derived Pharmaceutical Market, by Country,
Latin America Cannabinoid Derived Pharmaceutical Market, by Country,
Middle East & Africa Cannabinoid Derived Pharmaceutical Market, by Country,
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
